Results 181 to 190 of about 105,747 (297)
Shadow Banks and the Collateral Multiplier. [PDF]
Michl T, Park HW.
europepmc +1 more source
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen +12 more
wiley +1 more source
Hedging climate change risks in Southern Africa's agricultural industry using catastrophe bonds. [PDF]
Mutsvene T, Klingelhöfer HE.
europepmc +1 more source
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang +10 more
wiley +1 more source
The time-varying effects of geopolitical risk on mutual fund risk taking. [PDF]
Liu J, Chen Z, Zhu Y, Chen Y, Huang Y.
europepmc +1 more source
Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason +12 more
wiley +1 more source
Smart decision framework for financial planning and investment optimization. [PDF]
Chen X, Shen A.
europepmc +1 more source
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
Risk-taking responses to crash experience: Evidence from China. [PDF]
Fang Z, Xu H, Mu Y.
europepmc +1 more source

